CTLA4 and neoplasm: C57Bl6 mice bearing GD2<sup>+</sup> tumors received 4 or 15 Gy tumor-absorbed doses, determined by individualized dosimetry, with or without dual ICIs (anti-CTLA-4 and anti-PD-L1).